Cargando…

Novel lipid mediators contributing to androgen receptor therapy resistance in prostate cancer

Detalles Bibliográficos
Autor principal:	Chinni, Sreenivasa R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599995/ https://www.ncbi.nlm.nih.gov/pubmed/34775352 http://dx.doi.org/10.1016/j.ebiom.2021.103696

Ejemplares similares

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022)

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Protein translation controlled by the androgen receptor in prostate cancer: a novel therapeutic option?
por: Mirzakhani, Kimia, et al.
Publicado: (2020)

Towards understanding androgen receptor-independent prostate cancer: an evolving paradigm
por: Zhou, Jianfu, et al.
Publicado: (2020)

Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy
por: Zhang, Keke, et al.
Publicado: (2018)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
por: Ehsani, Marzieh, et al.
Publicado: (2021)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

A phosphorylation switch controls androgen biosynthesis in prostate cancer
por: Qiu, Yun
Publicado: (2023)

Androgen Receptor-Mediated Transcription in Prostate Cancer
por: Özturan, Doğancan, et al.
Publicado: (2022)

Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
por: Xu, Lingfan, et al.
Publicado: (2019)

Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
por: Denmeade, Samuel R, et al.
Publicado: (2023)

Statins and adrenal androgen levels in prostate cancer: A new twist
por: Mostaghel, Elahe A
Publicado: (2021)

Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
por: Jia, Lin, et al.
Publicado: (2018)

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
por: Zhang, Haozhe, et al.
Publicado: (2022)

Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer
por: Han, W, et al.
Publicado: (2018)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective
por: Collier, Tony, et al.
Publicado: (2020)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance
por: Lee, Eugine, et al.
Publicado: (2019)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
por: Crona, Daniel J., et al.
Publicado: (2017)

The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
por: Aragon-Ching, Jeanny B.
Publicado: (2014)

Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer
por: Zhao, Jingwen, et al.
Publicado: (2016)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
por: Cao, Bo, et al.
Publicado: (2014)

Effects of androgen deprivation therapy duration and Gleason grade on survival outcomes of high risk prostate cancer
por: Kim, Do Kyung, et al.
Publicado: (2019)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Androgen resistance in prostate cancer
por: Waxman, J, et al.
Publicado: (2008)

Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
por: Marques, Rute B., et al.
Publicado: (2010)

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
por: Marques, Rute B., et al.
Publicado: (2011)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis
por: Wong, Donald, et al.
Publicado: (2014)

Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression
por: Schaefer-Klein, J. L., et al.
Publicado: (2015)

Androgen Receptor Splice Variants Contribute to the Upregulation of DNA Repair in Prostate Cancer
por: Tolkach, Yuri, et al.
Publicado: (2022)

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
por: Vaishampayan, Ulka N., et al.
Publicado: (2021)

Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer
por: Gui, Bin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_63af7gjvp88toubanq23gmoans